Atenolol and Timolol, Two New Systemic β-Adrenoceptor Antagonists
- 17 June 1982
- journal article
- review article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 306 (24), 1456-1462
- https://doi.org/10.1056/nejm198206173062404
Abstract
ATENOLOL (Tenormin) and timolol (Blocadren) are two β-adrenoceptor antagonists recently released for clinical use in the United States (Fig. 1). They are the fourth and fifth systemic β-blockers to be approved by the Food and Drug Administration for the treatment of hypertension. Atenolol was released in 1981; like metoprolol, it is a β1-selective adrenergic blocker. However, unlike metoprolol, it has a long plasma half-life, which allows single daily doses in the treatment of hypertension.1 2 3 Timolol is a nonselective β-adrenergic blocker that has characteristics similar to those of propranolol but lacks membrane-stabilizing activity.1 It was approved by the FDA . . .Keywords
This publication has 43 references indexed in Scilit:
- Nadolol: A New β-Adrenoceptor AntagonistNew England Journal of Medicine, 1981
- β-Adrenoceptor Antagonists: New Drugs and New IndicationsNew England Journal of Medicine, 1981
- Clinical evaluation of atenolol in hypertensive patients.Circulation, 1981
- Timolol-Induced Reduction in Mortality and Reinfarction in Patients Surviving Acute Myocardial InfarctionNew England Journal of Medicine, 1981
- Atenolol: once-daily cardioselective beta blockade for angina pectoris.Circulation, 1980
- The effect of timolol vs placebo on angina pectoris.Circulation, 1980
- MetoprololNew England Journal of Medicine, 1979
- AtenololDrugs, 1979
- Effect of timolol versus propranolol on hypertension and hemodynamics.Circulation, 1976
- TimololDrugs, 1975